

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 11/03/2006

APPLICATION NO.	FILING D	DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/667,580	09/22/2	2003	David S. Haffner	GLAUKO.035A	9637	
20995	20995 7590 11/03/2006				EXAMINER	
KNOBBE N 2040 MAIN	AARTENS OI	DEAK, L	DEAK, LESLIE R			
FOURTEEN				ART UNIT	PAPER NUMBER	
IRVINE, CA	92614			3761		

Please find below and/or attached an Office communication concerning this application or proceeding.

	-	Application No.	Applicant(s)				
		10/667,580					
	Office Action Summary	Examiner	HAFFNER ET AL.				
,			Art Unit				
	The MAILING DATE of this communication app	Leslie R. Deak ears on the cover sheet with the	3761				
Period for Reply							
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 186(a). In no event, however, may a reply be tilt 186(a) in no event, however, howeve	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).				
Status							
1)🖂	Responsive to communication(s) filed on 30 Au	<u>ıgust 2006</u> .					
2a)⊠	This action is FINAL . 2b) This action is non-final.						
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	ion of Claims	1					
5)□ 6)⊠ 7)□	Claim(s) 1-12 is/are pending in the application. 4a) Of the above claim(s) 1 and 3-12 is/are with Claim(s) is/are allowed. Claim(s) 2 is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	ndrawn from consideration.					
Applicati	on Papers						
10)⊠	The specification is objected to by the Examiner The drawing(s) filed on <u>22 September 2003</u> is/a Applicant may not request that any objection to the o Replacement drawing sheet(s) including the correcti The oath or declaration is objected to by the Ex	re: a)⊠ accepted or b)⊡ object drawing(s) be held in abeyance. Se don is required if the drawing(s) is ob	e 37 CFR 1.85(a). ejected to. See 37 CFR 1.121(d).				
Priority u	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice Notice 3) Inform	e of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate				

Application/Control Number: 10/667,580 Page 2

Art Unit: 3761

DETAILED ACTION

Election/Restrictions

1. Newly submitted claim 12 is directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: The newly claimed method presents claims directed to the use of the claimed implant, but includes steps (such as introducing fluid from a location outside the eye) that were not originally considered by the examiner. It is the position of the examiner that the method may be performed by a materially different apparatus, since the claimed device does not provide any means to introduce fluid from a location outside the eye into Schlemm's canal via the implant. Therefore, the inventions are distinct and restrictable.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 12 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claim Rejections - 35 USC § 103

- 2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claim 2 is rejected under 35 U.S.C. 103(a) as being unpatentable over US 4,787,885 to Binder in view of US 6,626,858 to Lynch et al.

Art Unit: 3761

In the specification and figures, Binder discloses the device substantially as claimed by applicant. In particular, Binder discloses a glaucoma implant 10 with an outflow portion at base 12, a lumen 100 through the implant 10, an inflow portion at lip 16, and anchoring members comprising base 12 and lip 16 that maintain the implant in place (see column 3, lines 50 to column 4, line 67, FIGS). The implant is composed of a hydrogel, which is a hydrophilic polymer that allows aqueous solution to migrate through the edges of the device, meeting applicant's limitations drawn to openings in the implant (see column 4, lines 7-22). The shape of the implant allows it to be implanted within the eye regardless of rotational orientation (see FIG 1).

Binder fails to disclose that the implant is placed within Schlemm's canal, but discloses that the implant is designed to shunt aqueous from the anterior chamber to a subscleral space (see column 5, lines 23-29). Lynch discloses an implantable shunt for treating glaucoma with longitudinal axis (represented by arm 25) an outflow portion 25 that passes through the axis and is configured to be received within Schlemm's canal (see column 8, lines 1-34) at some angle (see FIG 6C). The device further comprises an inflow portion 10 that channels fluid from the anterior chamber of the eye through the shunt to the outflow portion (see column 7, lines 13-16). Lynch discloses that the placement of the implant in Schlemm's canal avoids the complications of shunting aqueous to the surface of the eye, preventing scarring and hypotony (see column 4, line 59 to column 5, line 11). Therefore, it would have been obvious to place the symmetrical implant with openings and anchor means disclosed by Binder at least partially within

Art Unit: 3761

Schlemm's canal, as disclosed by Lynch, in order to reduce scarring and hypotony, as taught by Lynch (see column 4, line 59 to column 5, line 11).

Response to Arguments

4. Applicant's arguments with respect to claim 2 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leslie R. Deak whose telephone number is 571-272-4943. The examiner can normally be reached on M-F 7:30-5:00, every other Friday off.

Art Unit: 3761

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tanya Zalukaeva can be reached on 571-272-1115. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Leslie R. Deak
Patent Examiner
Art Unit 3761

19 October 2006

PATRICIA BIANCO
PRIMARY EXAMINER